TY - JOUR T1 - Serum Alpha-tocopherol, Retinol and Neopterin during Paclitaxel/Carboplatin Chemotherapy JF - Anticancer Research JO - Anticancer Res SP - 4397 LP - 4401 VL - 27 IS - 6C AU - BOHUSLAV MELICHAR AU - HANA KALÁBOVÁ AU - LENKA KRČMOVÁ AU - LUBOR URBÁNEK AU - RADOMÍR HYŠPLER AU - EVA MALÍŘOVÁ AU - DAGMAR SOLICHOVÁ Y1 - 2007/11/01 UR - http://ar.iiarjournals.org/content/27/6C/4397.abstract N2 - Background: Disorders of antioxidant balance are considered to be involved in the toxicity associated with radiotherapy or chemotherapy. Patients and Methods: Serum alpha-tocopherol and retinol were determined, by high performance liquid chromatography, before and during therapy with a combination of paclitaxel and carboplatin in 28 patients with breast and ovarian cancer. Serum neopterin and cholesterol were measured using a radioimmunoassay and enzymatic colorimetric method, respectively. Results: Compared to pretreatment concentrations, a significant increase was observed in serum alpha-tocopherol and retinol concentrations during therapy that was associated with decreased serum neopterin concentrations. Serum alpha-tocopherol concentrations were significantly higher during therapy in patients who did not experience serious toxicity. Conclusion: An increase in alpha-tocopherol and retinol during therapy with combination paclitaxel/carboplatin may be explained by inhibition of systemic immune activation secondary to control of the tumor with effective chemotherapy. Lower alpha-tocopherol concentrations were associated with the toxicity of therapy. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -